Zenflow news page · May 2026
Zenflow highlighted presentation of BREEZE pivotal clinical trial results at AUA 2026.
Medical device that provides a more effective, less invasive…
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Zenflow is a South San Francisco medtech company developing and commercializing the Zenflow Spring system for benign prostatic hyperplasia (BPH), a minimally invasive, reversible treatment designed for office-based urology care.
Primary product
Zenflow Spring Implant and Delivery System (Spring)
Founded
2014
Headquarters
South San Francisco, California, United States
Team size
20-30
Industry
Medical Equipment Manufacturing
Sub-industry
Urology / BPH medical devices
Offices
South San Francisco, California, United States
Business model
medical device sale
procedure-enabling hardware
B2B clinical commercialization
Funding
Stage
Series C
Total raised
$80.2M
Latest round
Series C · Nov 2024
Latest amount
$24M
Nov 2024 · Cook Medical
Jun 2021 · Invus Opportunities
Sep 2019 · National Institutes of Health
Nov 2018 · Square 1 Bank
Feb 2018 · Invus Opportunities
People & investors
Leadership
CEO & Founder
COO
Gene Ramirez
CFO
SVP Clinical & Regulatory
VP R&D
Founders
Co-founder
Work & culture
Mission-driven, patient-centric, and startup-fast; the public messaging emphasizes clinical rigor, regulatory execution, and improving outcomes for men with BPH.
Compensation
Public job postings for senior roles list base salary bands of roughly $100k-$130k and $130k-$150k, plus equity and comprehensive benefits; broader compensation details are not publicly disclosed.
Benefits
comprehensive benefits
equity
Product & market
Pricing
Not publicly disclosed; appears to be a B2B medical-device/procedural commercialization model tied to clinical use and reimbursement.
Differentiators
- —reversible/removable treatment
- —office-based or outpatient procedure
- —flexible cystoscope delivery
- —no burning, cutting, piercing, or tissue removal
- —designed to preserve natural anatomy and sexual function
- —three implant sizes
- —largest working channel among single-use flexible cystoscopes (for Spring Scope)
Technology
Zenflow Spring implant
Zenflow Spring Scope
single-use flexible cystoscope
nitinol
superelastic shape-memory material
balloon anchor
HD visualization
SolidWorks
FDA QSR Part 820
ISO 13485
EU MDR
Customers
urologists
urology clinics
office-based procedural practices
ambulatory/outpatient settings
patients with BPH
Competitors
UroLift
Rezum
iTind
TURP
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
7.6K
Traffic estimate as of Jun 2026
Latest news
GlobeNewswire / Zenflow · Dec 2025
Zenflow announced FDA PMA approval of its Spring Implant and Delivery System for BPH.
GlobeNewswire / Zenflow · Sep 2025
Zenflow received FDA 510(k) clearance for the Spring Scope & Camera Control Unit, a single-use flexible cystoscope.
GlobeNewswire / Zenflow · Apr 2025
Three-year ZEST data showed durable symptom relief, including 74% responder rate at 36 months and preserved sexual function.
GlobeNewswire / Zenflow · Nov 2024
Zenflow closed a $24 million Series C financing round led by Cook Medical.
Jobs and careers at Zenflow
0 jobs at Zenflow
No open positions
Check back later for new openings